| Literature DB >> 28035946 |
Susana Campuzano1, Paloma Yáñez-Sedeño2, José M Pingarrón3.
Abstract
Early diagnosis is often the key to successful patient treatment and survival. The identification of various disease signaling biomarkers which reliably reflect normal and disease states in humans in biological fluids explain the burgeoning research field in developing new methodologies able to determine the target biomarkers in complex biological samples with the required sensitivity and selectivity and in a simple and rapid way. The unique advantages offered by electrochemical sensors together with the availability of high affinity and specific bioreceptors and their great capabilities in terms of sensitivity and stability imparted by nanostructuring the electrode surface with different carbon nanomaterials have led to the development of new electrochemical biosensing strategies that have flourished as interesting alternatives to conventional methodologies for clinical diagnostics. This paper briefly reviews the advantages of using carbon nanostructures and their hybrid nanocomposites as electrode modifiers to construct efficient electrochemical sensing platforms for diagnosis. The review provides an updated overview of some selected examples involving attractive amplification and biosensing approaches which have been applied to the determination of relevant genetic and protein diagnostics biomarkers.Entities:
Keywords: antibodies; carbon nanostructures; diagnosis; electrochemical affinity biosensors; graphene; oligonucleotides; proteins
Year: 2016 PMID: 28035946 PMCID: PMC5373011 DOI: 10.3390/diagnostics7010002
Source DB: PubMed Journal: Diagnostics (Basel) ISSN: 2075-4418
Figure 1Structure and models of carbon nanotubes in function of their number of walls. (A) Single-wall carbon nanotubes (SWCNTs) structures in function of their chirality (zigzag, armchair, and chiral); (B) double-walled carbon nanotubes (DWCNTs); and (C) multi-walled carbon nanotubes (MWCNTs) made up of several concentric shells. Reprinted from [7] with permission. Figure as originally published in Tîlmaciu, C.-M.; Morris, M.C. Carbon nanotube biosensors. Front. Chem. 2015, 3, 59. doi:10.3389/fchem.2015.00059.
Electrochemical DNA biosensors for diagnosis using carbon nanomaterials as electrode modifiers.
| Electrode | Type of Carbon Nanomaterial | Analyte | Sample | Technique | L.R. | LOD | Reference |
|---|---|---|---|---|---|---|---|
| Au electrode | PAMAM G4-MWCNTs | human cellular prions protein (PrPC) | spiked blood plasma | CV | 1 pM–10 μM | 0.5 pM | [ |
| Au electrode | MWCNTs-PPy-PAMAM G4 | real PCR samples | SWV | 1 fM–10 pM (15 nts synthetic target), 1–100 fM (75 nts synthetic targets) | 0.3 fM (for both target DNAs) | [ | |
| Au electrode | MWCNTs | Hepatitis C viral DNA and | EIS | 0.1 fM–1 pM (synthetic oligonucleotide from Hepatitis C virus) | 7 fM | [ | |
| GCE | GO | cancer-related | - | chronoamperometry | 1 fM–1 nM | 1 fM | [ |
| GCE | graphene/AuNR/PT | HPV DNA | serum samples | DPV | 1.0 × 10−13–1.0 × 10−10 M | 4.03 × 10−14 M | [ |
| CILE | ZrO2/graphene | PCR samples | DPV | 1.0 × 10−13–1.0 × 10−6 mol·L−1 | 3.23 × 10−14 M | [ | |
| GCE | SWCNTs/CFGO | - | DPV | 1 × 10−6–1 × 10−13 mol·L−1 | 7.27 × 10−14 M | [ | |
| GCE | graphene-MSGNs | DNA sequences correlated to Alzheimer, thrombin, ATP | - | DPV | - | - | [ |
| GCE | GSHs | mutated | - | DPV | - | - | [ |
CILE: carbon-ionic liquid electrode; CV: cyclic voltammetry; DPV: differential pulse voltammetry; EIS: electrochemical impedance spectroscopy; GCE: glassy carbon electrode; GSHs, graphene@mesoporous silica hybrids; GO: graphene oxide; GR/AuNR/PT: GR/Au nanorod/polythionine; HPV: human papillomavirus; L.R.: linear range; MSGNs: mesoporous materials; PAMAM, polyamidoamine; PPy: polypyrrole; PrPC: cellular prions protein; SWCNTs/CFGO: SWCNTs-carboxyl functionalized GO; SWV: square-wave voltammetry; ZrO2/GR: zirconia-graphene.
Figure 2Schematic display of the aptamer biosensor developed for the determination of PrPC using MWCNTs-PAMAM-Fc-biotin-streptavidin bioscaffolds. Reprinted from [26] with permission. PAMAM, polyamidoamine.
Figure 3Schematic representation of the steps involved in the biosensor developed for Mycobacterium tuberculosis rpoB gene using MWCNTs-PPy-PAMAM-Fc composite nanomaterial. Steps: (a) electropolymerization by cycling potential; (b) dendrimers attachment through electrochemical oxidation of PAMAM’s G4 amines; (c) Covalent attachment of ferrocene; (d) covalent attachment of DNA (wavy lines in green), bearing amine in 5′-position, in PBS at room temperature; (e) hybridization reaction with the DNA target (wavy lines in red). Reprinted from [8] with permission.
Figure 4(a) Schematic display of the microfluidic multiplexed electrochemical platform developed for specific genetic analysis of Mycobacterium tuberculosis and Hepatitis C DNA; (b) schematic illustration of the chemical patterning (steps 1, 2, and 3) used for the preparation of the biosensor based on modified ferrocene, as redox marker. Reprinted from [16] with permission.
Figure 5Schematic illustration of the target-responsive encapsulation assay (TRE) electrochemical biosensor for determination of various classes of biologically relevant molecules. Reprinted from [21] with permission.
Figure 6Schematic illustrations of the ratiometric electrochemical DNA sensor developed (A); and the electrochemical signal obtained (B). Reprinted from [12] with permission.
Electrochemical immunosensors involving CNTs-modified platforms for the determination of cancer and cardiovascular biomarkers.
| Electrode | Analyte | Immunoassay | Technique | Linear Range | LOD | Sample | Reference |
|---|---|---|---|---|---|---|---|
| Cancer biomarkers | |||||||
| AuNPs-HDT-AuNPs/MW-CILE | HER2 | Direct with immobilized anti-HER | EIS | 10–110 ng·mL−1 | 7.4 ng·mL−1 | serum | [ |
| MWCNTs-ZnONF/GCE | CA-125 | Direct with immobilized anti-CA-125. | DPV | 0.001–1000 U·mL−1 | 0.00113 U·mL−1 | spiked serum | [ |
| THI/MWCNTs/IL/GCE | PSA | Sandwich with immobilized anti-PSA and HRP-Ab2 | DPV | 0.2–1.0 ng·mL−1 1–40 ng·mL−1 | 20 pg·mL−1 | prostate tissue, serum | [ |
| MWCNTs/IL/Chit/GCE | PSA | Direct (EIS) with immobilized anti-PSA-AuNPs-PAMAM, or sandwich (DPV) with HRP-Ab2 | EIS | up to 25 ng·mL−1 up to 80 ng·mL−1 | 0.5 pg·mL−1 1 pg·mL−1 | serum | [ |
| MWCNTs/DAH/GCE | PSA | Sandwich with immobilized anti-PSA and Ab2-AuNPs-FcH | DPV | 0.01–100 ng·mL−1 | 5.4 pg·mL−1 | spiked human serum | [ |
| SWCNTs/GCE | NSE | Indirect competitive with immobilized NSE, anti-NSE, and AP-anti-IgG/AuNPs | DPV | 0.1–2000 ng·mL−1 | 0.033 ng·mL−1 | clinical serum specimens | [ |
| SWCNTs/Nafion/Fe(OH)x/PG | IL-6 | Sandwich with immobilized anti-IL6 and multi-HRP-MWCNTs-labeled-Ab2 | amperom | 0.5–30 pg·mL−1 | 0.5 pg·mL−1 | calf serum | [ |
| SWCNTs/TMCS-MPS/graphene/GCE | AFP | Direct with immobilized anti-AFP. | DPV | 0.1–100 ng·mL−1 | 0.06 ng·mL−1 | serum | [ |
| Au/PDDA/MWCNTs/(PSS/PDDA/MWCNTs)2/GCE | CEA | Direct with immobilized anti-CEA. | CV | 0.1–2.0; 2.0–160 ng·mL−1 | 0.06 ng·mL−1 | serum | [ |
| pTHI/PA6/MWCNTs/GCE | p53 | Sandwich with immobilized anti-p53 and HRP-Ab2 | DPV | 0.002–2 ng·mL−1 | <1 pg·mL−1 | - | [ |
| Cardiovascular biomarkers | |||||||
| PtNPs(MPA)/G-MWCNTs | cTn1 | Direct with immobilized anti-cTn1 | EIS | 0.001–10 ng·mL−1 | 1.0 pg·mL−1 | human serum | [ |
| SU-8/MWCNTs/GCE | Mb, cTn1, CK-MB | Direct with immobilized anti-Mb, or anti-cTnI, or anti-CK-MB | EIS | 1–50 (Mb); 0.1–10 (cTnI); 10–10,000 (CK-MB) ng·mL−1 | 0.1 (Mb; cTnI); 1 ng·mL−1 (CK-MB) | - | [ |
| CNTs/PEI/AuE | cTnT | Sandwich with immobilized anti-cTnT and Ab2-HRP | amperom. | 0.1–10 ng·mL−1 | 0.033 ng·mL−1 | human serum | [ |
| NH2-MWCNTs/SPE | cTnT | Direct with immobilized anti-cTnT. | DPV | 0.0025–0.5 ng·mL−1 | 0.0035 ng·mL−1 | serum | [ |
| MWCNTs/SPE | Mb | Direct with immobilized anti-Mb | EIS | 0.1–90 ng·mL−1 | 0.08 ng·mL−1 | serum | [ |
| MWCNTs/THI/AuNPs/GCE | MPO | Direct with immobilized anti-MPO. | CV | 2.5–125 ng·mL−1 | 1.425 ng·mL−1 | human serum | [ |
| p | MPO | Direct with immobilized anti-MPO | amperom. | 0.2–23.4 ng·mL−1 23.4–300 ng·mL−1 | 0.05 ng·mL−1 | human serum | [ |
| Cyst/SPAuE | oxLDL | Direct with immobilized anti-oxLDL | SWV | 3–10.5 μg·mL−1 0.5–18.0 μg·mL−1 | 0.22 μg·mL−1 | serum | [ |
| p-MWCNTs@Chit/Nafion/THI/Au NPs/GCE | netrin 1 | Direct with immobilized anti-netrin 1 | DPV | 0.09–1800 pg·mL−1 | 30 fg·mL−1 | serum | [ |
| AuNPs-CNTs/AuE | NT-proBNP | Sandwich with immobilized anti-NT-proBNP and HRP-Ab2-AuNCs | CV | 0.02–100 ng·mL−1 | 6 pg·mL−1 | - | [ |
FCA, ferrocene carboxylic acid; MW-CILE, multi-walled carbon nanotubes-ionic liquid paste electrode; DAH, 1,7-diaminoheptane; FcH, 6-ferrocenylhexanethiol; HDT, 1,6-hexanedithiol; Mb, myoglobin; MPA, 3-mercaptopropionic; MPO, myeloperoxidase; MPS, mesoporous silica; PA6, a type of Nylon; PDDA, polydiallyldimethyl ammonium; PG, pyrolytic graphite; poPD, poly(o-phenylenediamine); PSS, poly(sodium-p-styrene-sulfonate); THI, thionine; IL, ionic liquid; TMCS, trimethylchlorosilane; ZnONF, ZnO nanofibers; ITO, indium tin oxide.
Figure 7Schematic representation of stepwise fabrication of the anti-cTnI-PtMPA/GR-MWCNTs/GCE immunosensor. Reprinted from [61] with permission.
Figure 8Scheme of the fabrication steps o fNT-proBNP immunosensor using AuNCs-HRP-Ab2 and AuNPs-CNTs nanocomposites. Reprinted from [74] with permission.
Electrochemical immunosensors involving graphene-modified platforms for the determination of cancer and cardiovascular biomarkers.
| Electrode | Analyte | Immunoassay | Technique | Linear Range | LOD | Sample | Reference |
|---|---|---|---|---|---|---|---|
| Cancer biomarkers | |||||||
| Strept-AuNPs-SH-GO/GCE | p53 | Sandwich with immobilized Biotin-anti-p53 and HRP-Ab2 | DPV | 0.2–2 pmol·L−1 2–200 pmol·L−1 | 30 pmol L−1 | human serum | [ |
| SnO2/AuNPs/rGO/GCE | AFP | Direct with immobilized anti-AFP. [Ru(NH3)6]3+ as the redox probe. | DPV | 0.02–50 ng·mL−1 | 0.01 ng·mL−1 | spiked serum | [ |
| AuNPs/NB/rGO/GCE | CEA | Direct with immobilized anti-CEA. Nile Blue (NB) as the redox probe | DPV | 0.001–40 ng·mL−1 | 0.00045 ng·mL−1 | spiked serum | [ |
| GO-SPCE | CA 153 | Sandwich with immobilized anti-CA153 and Ab2-ZnFe2O4/GO | DPV | 10−3–200 U·mL−1 | 2.8 × 10−4 U·mL−1 | spiked serum | [ |
| 3D-rGO/AuNPs/ | PSA | Direct with immobilized anti-PSA. [Fe(CN)6]3−/4− as the redox probe | CV | up to 10 ng·mL−1 | 0.59 ng·mL−1 | - | [ |
| APTES/ZrO2-rGO/ITO | CYFRA-21-1 | Direct with immobilized anti-CYFRA-21-1. [Fe(CN)6]3−/4− as the redox probe | DPV | 2–22 ng·mL−1 | 0.122 ng·mL−1 | saliva | [ |
| Ag/Au–DN–graphene/GCE | CEA | Sandwich with immobilized anti-CEA and Ab2-Ag/Au–DN-graphene | Amperometry | 0.01–1200 ng·mL−1 | 8 pg·mL−1 | spiked human plasma | [ |
| AuPdPtNPs/rGO/TEPA/GCE | NMP22 | Direct with immobilized anti-NMP22. [Fe(CN)6]3−/4− as the redox probe | DPV | 0.040–20 U·mL−1 | 0.01 U·mL−1 | urine | [ |
| Cardiovascular biomarkers | |||||||
| PrGO/GCE | cTnI | Direct with immobilized anti-TnI | EIS | 0.1–10 ng·mL−1 | 0.07 ng·mL−1 | - | [ |
| PtNPs(MPA)/EG/GCE | cTnI | Direct with immobilized anti-TnI | EIS | 0.01–10 ng·mL−1 | 4.2 pg·mL−1 | - | [ |
| AuNPs-Ph-GO/GCE | cTnI | Direct with immobilized anti-cTnI-Fc-GO. [Fe(CN)6]3−/4− as the redox probe | SWV | 0.05–3 ng·mL−1 | 0.05 ng·mL−1 | spiked serum | [ |
| PtMPA/GR-MWCNTs/GCE | cTnI | Direct with immobilized anti-TnI | EIS | 0.001–10 ng·mL−1 | 0.001 ng·mL−1 | - | [ |
DN, 1,5-diaminonaphthalene; EG, electroactive graphene; MPA, 3-mercaptopropionic acid; PMA, 1-pyrenemethylamine; PrGO, porous graphene oxide; TEPA, tetraethylene pentamine.
Figure 9Schematic representation of the CA-15-3 immunosensor preparation using MSNPs/GO as signaling labels. Reprinted from [82] with permission.
Figure 10Scheme of the preparation of GO-Phe-AuNP nanocomposites (AuNP A indicates AuNP modified with mixed layers of PEG, 4-carboxyphentl and 4-nitrophenyl; AuNP B indicates AuNP modified with mixed layers of PEG, 4-carboxyphentl and 4-aminephenyl) (a); the preparation of ferrocene-GO-modified detection antibody (b); and the fabrication of the cTnI immunosensor (c). Reprinted from [87] with permission.